Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A healthy male or female, 19 to 64 years of age (not having reached the 65th birthday) at the time of study vaccination.~Exclusion Criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding administration of study vaccine, or planned use during the active phase of the study.~* Chronic administration of immunosuppressants or within six months prior to administration of study vaccine.~* Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days of administration of study vaccine (with the exception of an influenza vaccine).~* Administration of a diphtheria-tetanus (Td) booster within previous five years.~* Administration of Tdap vaccine at any time prior to study entry. History of serious allergic reaction (e.g. anaphylaxis) following any other tetanus toxoid, diphtheria toxoid or pertussis-containing vaccine or any component of the study vaccines.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Boostrix Group (Type: EXPERIMENTAL): Subjects, male or female, between, and including, 19 and 64 years of age received a single dose of Boostrix® vaccine administered intramuscularly in the deltoid region of the non-dominant upper arm at Day 0.
- Adacel Group (Type: EXPERIMENTAL): Subjects, male or female, between, and including, 19 and 64 years of age received a single dose of Adacel™ vaccine administered intramuscularly in the deltoid region of the non-dominant upper arm at Day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).